10 May 2022 : Original article
Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study
Bruno Roche1BCDE, Artur Bauhofer2ACDEF*, Miguel Ãngel Gomez Bravo3BCDE, Georges Philippe Pageaux4ABCDE, Fabien Zoulim5BDE, Alejandra Otero6BC, Martin Prieto78BC, Carmen Baliellas9BC, Didier Samuel1ACDEDOI: 10.12659/AOT.936162
Ann Transplant 2022; 27:e936162
Table 2 Post-transplant treatment with sc HBIg, concomitant antiviral medications, and anti-HBs serum levels.
| Full analysis set (N=195) | |||
|---|---|---|---|
| 91.7 (±94.1) | |||
| 20.7 (±7.4) | |||
| , * | 1171 (±546) | ||
| , * | |||
| <71.4 | 158 (81.0) | ||
| 71.4 (eq. to 500 IU/week) | 33 (16.9) | ||
| >71.4 | 2 (1.0) | ||
| Missing information | 2 (1.0) | ||
| Frequency of dosing regimens, n (%)** | |||
| 500 IU weekly | 107 (54.9) | ||
| 500 IU biweekly | 134 (68.7) | ||
| 500 IU every 3 weeks | 66 (33.8) | ||
| 500 IU every 4 weeks/monthly | 68 (34.9) | ||
| 1000 IU weekly | 6 (3.1) | ||
| 1000 IU biweekly | 1 (0.5) | ||
| 1000 IU monthly | 10 (5.1) | ||
| Other | 12 (6.2) | ||
| Missing information | 1 (0.5) | ||
| None | 84 (43.1) | ||
| At least 1 change (max. 6 changes) | 111 (56.9) | ||
| 159 (81.5) | |||
| 18 (9.2) | |||
| 2 (1.0) | |||
| 2 (1.0) | |||
| Patients with data available, n | 170 | 112 | 194 |
| Median (min, max) [IU/L] | 199.1 (36, 1000) | 144.0 (11, 558) | 140.1 (11, 1000) |
| * Averaged over the entire treatment period of a patient; ** regimens/treatments documented over entire observation period; due to treatment changes, patients may have been counted in more than one category. FU – follow up; HBIg – hepatitis B immunoglobulin; im – intramuscular; IU – international unit; iv – intravenous; LT – liver transplantation; SD – standard deviation. | |||